Purpose This phase II study (S0341) evaluated the efficacy and tolerability of single-agent
erlotinib in unselected chemotherapy-naive patients with advanced non-small cell lung …

Purpose A multicenter randomized phase II trial to evaluate two treatment strategies in the
first-line management of advanced non–small-cell lung cancer (NSCLC) patients with a …

Introduction The aim of this study was to evaluate the efficacy and safety of Erlotinib in
Japanese patients with previously treated non-small cell lung cancer (NSCLC). Available …

7536 Background: Patients (pts) with advanced NSCLC and PS 2 have an inferior survival
compared with good PS pts. Single agent and combination chemotherapy have been used …

Erlotinib is a highly potent inhibitor of epidermal growth factor receptor tyrosine-kinase
activity that significantly prolongs overall survival in patients with non-small-cell lung cancer …

7010 Background: Oral erlotinib is a potent HER1/EGFR tyrosine kinase-phosphorylation
inhibitor with single-agent antitumor activity and has shown additive effects when added to …

Purpose: Erlotinib has proven activity in pretreated patients with advanced non–small cell
lung cancer (NSCLC). We evaluated erlotinib in the frontline treatment of advanced NSCLC …

Purpose Erlotinib is a potent reversible HER1/epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor with single-agent activity in patients with non–small-cell lung cancer …

BACKGROUND. Erlotinib is an orally available, reversible inhibitor of epidermal growth
factor receptor (EGFR) with a proven survival advantage for patients with locally advanced …

Background: Erlotinib is a selective epidermal growth factor receptor tyrosine kinase
inhibitor (EGFR-TKI). We conducted two phase II studies (JO16565 and JO18396) of …